The study, led by Ross Levine of Memorial Sloan Kettering Cancer Center, leverages the Tapestri Platform’s unique DNA + Protein capabilities to elucidate the complexity of acute myeloid leukemia (AML)
SOUTH SAN FRANCISCO, Calif. (October 28, 2020) Mission Bio, Inc., the pioneer in single-cell DNA and multi-omics analysis, today announced the publication of a study demonstrating the power of its Tapestri® Platform to characterize the relationship between disease evolution and clonality in myeloid malignancies, including acute myeloid leukemia (AML). The Tapestri Platform’s industry-first capabilities allowed the researchers to correlate genotype and immunophenotype with single-cell resolution, providing novel insight into disease complexity and treatment resistance. The study, published in Nature, was led by Ross Levine, MD, at Memorial Sloan Kettering Cancer Center (MSK).
Progression of myeloid malignancies, including acute myeloid leukemia, is driven by the proliferation of cells that acquire mutations. While the mutational landscape of myeloid malignancies has been well characterized by bulk sequencing, challenges have remained in determining the order of mutation acquisition, mutation co-occurrence in the same clones or cell populations, and how that impacts disease progression. Additionally, insight into how specific genotypes affect protein expression, and the genotype-immunophenotype connection, has not been widely characterized at the single-cell level. To develop better treatments for complex diseases, clinicians and researchers need a holistic view of clonality and its complexity at both the genotype and phenotype level.
Leveraging Mission Bio’s Tapestri Platform, researchers at MSK used the Tapestri Platform, Tapestri Single-cell DNA Panels, and custom oligo-conjugated antibodies for single-cell DNA analysis and simultaneous single-cell mutation and protein profiling. A total of 146 samples from 123 AML patients were analyzed, and more than 700,000 cells were sequenced. They determined that the level of clonal complexity rises with disease progression. In particular, not all mutation combinations are equal, and where some show clonal dominance under therapeutic stressors, others do not, suggesting potentially therapeutic and prognostic implications. Finally, leveraging the Tapestri Platform’s industry-first DNA + Protein capabilities, the researchers determined how genotypic differences impact cell-surface protein expression, furthering a holistic view of the relationship between genotype and phenotype and disease progression.
“Our research with the Tapestri Platform gave us a glimpse into the molecular makeup of myeloid leukemia, one cell, one clone at a time,” said Levine, also a member of the Mission Bio Scientific Advisory Board. “Without the ability to detect mutations and protein from the same cells, this level of insight and understanding would not be possible.”
The study comes not long after the first peer-reviewed publication showcasing the unique single-cell multi-omics capabilities of the Tapestri Platform, published earlier this month in Nature Communications.
“With this tremendous work, Dr. Levine and his team further demonstrate the power of simultaneously detecting genotype and phenotype at the single-cell level,” said Charlie Silver, co-founder, and CEO of Mission Bio. “The Tapestri Platform was built to enable clinicians and researchers to unravel therapeutic response and resistance, and we are excited at the impact in myeloid malignancies and other disease areas.”
The full peer-reviewed study can be found here. To learn more about Mission Bio and how it is helping unravel the complexity of cancer, visit missionbio.com.
About Mission Bio
Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology helps discern key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation.
Researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.
Dr. Ross Levine serves on the Scientific Advisory Board for Mission Bio and has associated financial interests with the company by virtue of this role.
Media Contact:
Kathryn Ryan
VSC for Mission Bio
missionbio@vsc.co
(631) 255-5281
